ada standards of care 2025 glp-1 receptor agonists recommendations New EASD-ADA consensus guidelines on managing hyperglycaemia in type 2 diabetes launched at EASD meeting. New include specific drug classes for some patients and enhancing medication adherence – Diabetologia ADA Standards of Care in

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Learn what GLP-1 medications are, how they work, and which conditions they are used to treat.

This is a huge market